AKT1 is altered in 0.59% of renal cell carcinoma patients [2].

AKT1 is an inclusion eligibility criterion in 2 clinical trials for renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT1 status and renal cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

AKT2 is altered in 1.1% of renal cell carcinoma patients [2].

AKT2 is an inclusion eligibility criterion in 2 clinical trials for renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT2 status and renal cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

AKT3 is altered in 0.22% of renal cell carcinoma patients [2].

AKT3 is an inclusion eligibility criterion in 2 clinical trials for renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT3 status and renal cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

ALK is altered in 1.72% of renal cell carcinoma patients [2].

ALK is an inclusion eligibility criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ARAF is altered in 0.44% of renal cell carcinoma patients [2].

ARAF is an inclusion eligibility criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and renal cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ATM is altered in 4.54% of renal cell carcinoma patients [2].

ATM is an inclusion eligibility criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

AXL is altered in 0.58% of renal cell carcinoma patients [2].

AXL is an inclusion eligibility criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AXL status and renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BAP1 is altered in 13.17% of renal cell carcinoma patients [2].

BAP1 is an inclusion eligibility criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 status and renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BARD1 is altered in 0.47% of renal cell carcinoma patients [2].

BARD1 is an inclusion eligibility criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 status and renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BRAF is altered in 0.85% of renal cell carcinoma patients [2].

BRAF is an inclusion eligibility criterion in 3 clinical trials for renal cell carcinoma, of which 3 are open and 0 are closed. Of the trials that contain BRAF status and renal cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].

BRCA1 is altered in 1.87% of renal cell carcinoma patients [2].

BRCA1 is an inclusion eligibility criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 status and renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BRCA2 is altered in 2.71% of renal cell carcinoma patients [2].

BRCA2 is an inclusion eligibility criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BRIP1 is altered in 0.74% of renal cell carcinoma patients [2].

BRIP1 is an inclusion eligibility criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRIP1 status and renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK12 is altered in 0.7% of renal cell carcinoma patients [2].

CDK12 is an inclusion eligibility criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 status and renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CHEK1 is altered in 0.46% of renal cell carcinoma patients [2].

CHEK1 is an inclusion eligibility criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK1 status and renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CHEK2 is altered in 1.54% of renal cell carcinoma patients [2].

CHEK2 is an inclusion eligibility criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK2 status and renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CRKL is altered in 0.29% of renal cell carcinoma patients [2].

CRKL is an inclusion eligibility criterion in 2 clinical trials for renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CRKL status and renal cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

EGFR is altered in 1.23% of renal cell carcinoma patients [2].

EGFR is an inclusion eligibility criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ERBB2 is altered in 1.11% of renal cell carcinoma patients [2].

ERBB2 is an inclusion eligibility criterion in 2 clinical trials for renal cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERBB2 status and renal cell carcinoma as inclusion criteria, 2 are phase 1 (1 open) [3].

FANCL is an inclusion eligibility criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCL status and renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FH is altered in 2.31% of renal cell carcinoma patients [2].

FH is an inclusion eligibility criterion in 7 clinical trials for renal cell carcinoma, of which 4 are open and 3 are closed. Of the trials that contain FH status and renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (0 open), and 5 are phase 2 (4 open) [3].

FLCN is altered in 1.27% of renal cell carcinoma patients [2].

FLCN is an inclusion eligibility criterion in 1 clinical trial for renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FLCN status and renal cell carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

HRAS is altered in 0.33% of renal cell carcinoma patients [2].

HRAS is an inclusion eligibility criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and renal cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

IDH1 is altered in 0.2% of renal cell carcinoma patients [2].

IDH1 is an inclusion eligibility criterion in 1 clinical trial for renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains IDH1 status and renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

IDH2 is altered in 0.41% of renal cell carcinoma patients [2].

IDH2 is an inclusion eligibility criterion in 1 clinical trial for renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains IDH2 status and renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

KRAS is altered in 0.98% of renal cell carcinoma patients [2].

KRAS is an inclusion eligibility criterion in 3 clinical trials for renal cell carcinoma, of which 2 are open and 1 is closed. Of the trials that contain KRAS status and renal cell carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

MAP2K1 is altered in 0.43% of renal cell carcinoma patients [2].

MAP2K1 is an inclusion eligibility criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and renal cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP2K2 is altered in 0.37% of renal cell carcinoma patients [2].

MAP2K2 is an inclusion eligibility criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 status and renal cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP2K4 is altered in 0.44% of renal cell carcinoma patients [2].

MAP2K4 is an inclusion eligibility criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 status and renal cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP3K1 is altered in 1.23% of renal cell carcinoma patients [2].

MAP3K1 is an inclusion eligibility criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 status and renal cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAPK1 is altered in 0.16% of renal cell carcinoma patients [2].

MAPK1 is an inclusion eligibility criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAPK1 status and renal cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MET is altered in 3.94% of renal cell carcinoma patients [2].

MET is an inclusion eligibility criterion in 2 clinical trials for renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MET status and renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

MTOR is altered in 7.14% of renal cell carcinoma patients [2].

MTOR is an inclusion eligibility criterion in 2 clinical trials for renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MTOR status and renal cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

MYC is altered in 0.8% of renal cell carcinoma patients [2].

MYC is an inclusion eligibility criterion in 1 clinical trial for renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC status and renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NF1 is altered in 2.79% of renal cell carcinoma patients [2].

NF1 is an inclusion eligibility criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NF1 status and renal cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NRAS is altered in 0.13% of renal cell carcinoma patients [2].

NRAS is an inclusion eligibility criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and renal cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PALB2 is altered in 1.32% of renal cell carcinoma patients [2].

PALB2 is an inclusion eligibility criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 status and renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRA is altered in 1.05% of renal cell carcinoma patients [2].

PDGFRA is an inclusion eligibility criterion in 2 clinical trials for renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PDGFRA status and renal cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

PIK3CA is altered in 3.36% of renal cell carcinoma patients [2].

PIK3CA is an inclusion eligibility criterion in 2 clinical trials for renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PIK3CA status and renal cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

PIK3CG is altered in 2.01% of renal cell carcinoma patients [2].

PIK3CG is an inclusion eligibility criterion in 2 clinical trials for renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PIK3CG status and renal cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

PIK3R1 is altered in 1.43% of renal cell carcinoma patients [2].

PIK3R1 is an inclusion eligibility criterion in 2 clinical trials for renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PIK3R1 status and renal cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

PIK3R2 is altered in 0.46% of renal cell carcinoma patients [2].

PIK3R2 is an inclusion eligibility criterion in 2 clinical trials for renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PIK3R2 status and renal cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

PPP2R2A is altered in 0.52% of renal cell carcinoma patients [2].

PPP2R2A is an inclusion eligibility criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PPP2R2A status and renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PTEN is altered in 5.65% of renal cell carcinoma patients [2].

PTEN is an inclusion eligibility criterion in 2 clinical trials for renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and renal cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

RAD51B is an inclusion eligibility criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAD51C is altered in 0.4% of renal cell carcinoma patients [2].

RAD51C is an inclusion eligibility criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51C status and renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAD51D is altered in 0.2% of renal cell carcinoma patients [2].

RAD51D is an inclusion eligibility criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAD54L is altered in 0.26% of renal cell carcinoma patients [2].

RAD54L is an inclusion eligibility criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD54L status and renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAF1 is altered in 0.44% of renal cell carcinoma patients [2].

RAF1 is an inclusion eligibility criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and renal cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RET is altered in 1.25% of renal cell carcinoma patients [2].

RET is an inclusion eligibility criterion in 3 clinical trials for renal cell carcinoma, of which 3 are open and 0 are closed. Of the trials that contain RET status and renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

RICTOR is altered in 0.83% of renal cell carcinoma patients [2].

RICTOR is an inclusion eligibility criterion in 2 clinical trials for renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RICTOR status and renal cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

ROS1 is altered in 2.41% of renal cell carcinoma patients [2].

ROS1 is an inclusion eligibility criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RPTOR is altered in 0.82% of renal cell carcinoma patients [2].

RPTOR is an inclusion eligibility criterion in 2 clinical trials for renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RPTOR status and renal cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

SDHA is altered in 1.77% of renal cell carcinoma patients [2].

SDHA is an inclusion eligibility criterion in 3 clinical trials for renal cell carcinoma, of which 1 is open and 2 are closed. Of the trials that contain SDHA status and renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (1 open) [3].

SDHB is altered in 0.53% of renal cell carcinoma patients [2].

SDHB is an inclusion eligibility criterion in 4 clinical trials for renal cell carcinoma, of which 1 is open and 3 are closed. Of the trials that contain SDHB status and renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (1 open) [3].

SDHC is altered in 0.31% of renal cell carcinoma patients [2].

SDHC is an inclusion eligibility criterion in 4 clinical trials for renal cell carcinoma, of which 1 is open and 3 are closed. Of the trials that contain SDHC status and renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (1 open) [3].

SDHD is altered in 0.3% of renal cell carcinoma patients [2].

SDHD is an inclusion eligibility criterion in 4 clinical trials for renal cell carcinoma, of which 1 is open and 3 are closed. Of the trials that contain SDHD status and renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (1 open) [3].

SMARCB1 is altered in 1.74% of renal cell carcinoma patients [2].

SMARCB1 is an inclusion eligibility criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

SRC is altered in 0.38% of renal cell carcinoma patients [2].

SRC is an inclusion eligibility criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SRC status and renal cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

STK11 is altered in 0.65% of renal cell carcinoma patients [2].

STK11 is an inclusion eligibility criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains STK11 status and renal cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TFE3 is altered in 2.44% of renal cell carcinoma patients [2].

TFE3 is an inclusion eligibility criterion in 3 clinical trials for renal cell carcinoma, of which 1 is open and 2 are closed. Of the trials that contain TFE3 status and renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (1 open) [3].

TFEB is altered in 3.23% of renal cell carcinoma patients [2].

TFEB is an inclusion eligibility criterion in 2 clinical trials for renal cell carcinoma, of which 0 are open and 2 are closed. Of the trials that contain TFEB status and renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (0 open) [3].

TSC1 is altered in 4.19% of renal cell carcinoma patients [2].

TSC1 is an inclusion eligibility criterion in 2 clinical trials for renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain TSC1 status and renal cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

TSC2 is altered in 3.29% of renal cell carcinoma patients [2].

TSC2 is an inclusion eligibility criterion in 2 clinical trials for renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain TSC2 status and renal cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

VHL is altered in 46.89% of renal cell carcinoma patients [2].

VHL is an inclusion eligibility criterion in 4 clinical trials for renal cell carcinoma, of which 3 are open and 1 is closed. Of the trials that contain VHL status and renal cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 3 are phase 2 (3 open) [3].